Search results
Showing 7981 to 7995 of 8975 results
Endoluminal gastroplication for gastro-oesophageal reflux disease (IPG404)
Interventional procedures, IPG404 - Issued: July 2011 --> This guidance has been updated and replaced by NICE HealthTech guidance 661.
Interventional procedures, IPG418 - Issued: January 2012 --> This guidance has been updated and replaced by NICE HealthTech guidance 662.
In development Reference number: GID-TA11655 Expected publication date: TBC
In development Reference number: GID-TA11581 Expected publication date: TBC
Pembrolizumab–vibostolimab for untreated metastatic non-small-cell lung cancer [ID6365]
Discontinued Reference number: GID-TA11442
This guidance has been updated and replaced by NICE's technology appraisal guidance on bevacizumab (originator and biosimilars) with fluoropyrimidine-based chemotherapy for metastatic colorectal cancer (TA1136).
Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer (TA118)
This guidance has been updated and replaced by NICE's technology appraisal guidance on cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy (TA242) and bevacizumab (originator and biosimilars) with fluoropyrimidine-based chemotherapy for metastatic colorectal cancer (TA1136).
Discontinued Reference number: GID-TA10843
This guidance has been withdrawn because Cartiva Synthetic Cartilage Implant (SCI) has been recalled, and the evidence for this guidance was based solely on Cartiva SCI. More information is available in the field safety notice issued by Stryker. Surgeons are advised not to implant this device, to return any unused devices to Stryker and to consider reviewing any patients who have had Cartiva SCI. NICE will consider issuing new guidance on synthetic cartilage implant insertion for first metatarsophalangeal joint osteoarthritis (hallux rigidus) if evidence using an appropriately CE-marked device becomes available.
Leadless cardiac pacemaker implantation for bradyarrhythmias (HTG484)
This guidance has been updated and replaced by NICE HealthTech guidance 770.
Discontinued Reference number: GID-TAG380
Burosumab for treating FGF23-related hypophosphataemia in tumour-induced osteomalacia [ID3924 ]
Discontinued Reference number: GID-TA10822
Duvelisib for treating relapsed or refractory peripheral T-cell lymphoma [ID5076]
Discontinued Reference number: GID-TA10961
Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]
Discontinued Reference number: GID-TA11569